Therapeutic Angiogenesis Using Basic Fibroblast Growth Factor in Combination with a Collagen Matrix in Chronic Hindlimb Ischemia

<table>Hematoxylin-eosin analysis for revascularization in the muscles of the ischemic hindlimb 4 weeks after implantation. (a) No treatment; (b) bFGF; (c) CM; (d) bFGF-CM (<svg height="11.1" id="M24" style="vertical-align:-0.17555pt" version="1.1" viewbox="0 0 55.099998 11.1" width="55.099998" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,11.1)">
<g transform="translate(72,-63.12)">
<text transform="matrix(1,0,0,-1,-71.95,63.35)">
<tspan style="font-size: 12.50px; " x="0" y="0">b</tspan>
<tspan style="font-size: 12.50px; " x="6.2515001" y="0">a</tspan>
<tspan style="font-size: 12.50px; " x="11.802832" y="0">r</tspan>
<tspan style="font-size: 12.50px; " x="19.429663" y="0">=</tspan>
<tspan style="font-size: 12.50px; " x="31.470051" y="0">5</tspan>
<tspan style="font-size: 12.50px; " x="37.72155" y="0">0</tspan>
</text>
</g>
</g>
</svg> <i>μ</i>m).</table>

The Scientific World Journal

fig4

Figure 4

Figure 4: Therapeutic Angiogenesis Using Basic Fibroblast Growth Factor in Combination with a Collagen Matrix in Chronic Hindlimb Ischemia 